First FDA-Approved Treatment for Myelofibrosis, Jakafi? (ruxolitinib), Discus bi13751723 SAN DIEGO--(BUSINESS WIRE)--Incyte Corporation (Nasdaq:INCY) today announced that further analyses from the global, pivotal Phase III clinical program of Jakafi (ruxolitinib or INC424) are being presented at the 2011 American Society of Hematology (ASH) Annual Meeting. The presentations include: Verstovsek S, et al. Consistent benefit of ruxolitinib over placebo spleen volume reduction and ..

Dr. Paul Donohue: Shingles' effects can linger for years bi13751723 Dear Dr. Donohue: Two years ago I had shingles, and I now suffer the aftereffects of it. The sores went away a month, but the stinging, burning, throbbing pain me. I cannot wear clothing over the affected shoulder. No medicines have eased the pain so far. Is there any help?..

Gene first linked to herpes-related cold sores bi13751723 Researchers have identified the first gene associated frequent herpes-related cold sores

Tropical disease experts report missed opportunity to transform global HIV/AI bi13751723 ( Burness Communications ) Global HIV/AIDS prevention and efforts are missing a major opportunity to significantly improve health conditions poor countries by simply adding low-cost care for the many other chronic and disabling diseases routinely afflicting and often killing these same patients, according to a panel of disease experts who spoke at the annual meeting of the American ..

Prioritizing HIV/AIDS prevention and treatment bi13751723 In ForeignPolicy.com column, Charles Kenny, a senior fellow at the Center for Global Development and a Schwartz fellow at the New America Foundation, writes that despite an "abundance of tools to fight the global AIDS epidemic," including male circumcision and as prevention, "the breakthroughs don't amount to a global reprieve."..

First FDA-Approved Treatment for Myelofibrosis, Jakafi? (ruxolitinib), Discus bi13751723 SAN DIEGO--(BUSINESS WIRE)--Incyte Corporation (Nasdaq:INCY) today announced that further analyses from the global, pivotal Phase III clinical program of Jakafi (ruxolitinib or INC424) are being presented at the 2011 American Society of Hematology (ASH) Annual Meeting. The presentations include: Verstovsek S, et al. Consistent benefit of ruxolitinib over placebo spleen volume reduction and ..

Cardinal Health Selects Zymaderm? for Painless, Safe and Effective Treatm bi13751723 Naturopathix announces that Cardinal Health selects ZymaDerm? for painless, safe and effective of molluscum contagiosum for distribution to leading pharmacies nationwide. It joins distributors Smith Drug and drugstore chains that include Walgreens's and Pharmaca Integrative Pharmacies that sell ZymaDerm? stores, as well as leading online merchants that include Drugstore.com ..

AIDS Research Holds Promise for Reducing HIV Transmission Rates bi13751723 THURSDAY, Dec. 1 (HealthDay News) -- The data may at first seem dire: More people are living HIV/AIDS than ever before the United States, according to the U.S. Centers for Disease Control and Prevention

Molecules to Medicine: Should pepper spray be put on (clinical) trial? bi13751723 Pepper spray all over the news, following the Occupy Wall Street protests, particularly following the widely disseminated images and videos of protestors being sprayed NY, Portland, and UCDavis . Before that, I knew and occasionally used main ingredient, capsaicin, as a for my patients shingles, an extremely painful Herpes zoster infection. And I knew about the many of ..

Ultraviolet rays believed to prevent chickenpox spreading bi13751723 Ultraviolet rays help prevent the spread of chickenpox, meaning people milder climates are more at risk of catching the disease, according to new research. The discovery could lead to new ways of preventing chickenpox and more severe relative, shingles

Shingles outbreak often lingers bi13751723 Dear Dr. Donohue ? Two years ago I had shingles, and I now suffer the aftereffects of it. I cannot wear clothing over the affected shoulder. No medicines have eased the pain. Is there any help? ? M.L

Incyte announces further analyses from Jakafi Phase III trial on myelofibrosis bi13751723 Incyte Corporation today announced that further analyses from the global, pivotal Phase III clinical program of Jakafi (ruxolitinib or INC424) are being presented at the 2011 American Society of Hematology (ASH) Annual Meeting

Aids-related infection the primary killer bi13751723 South Africa has an estimated 5.7-million people living HIV and Aids, more than any other country on Earth

Brake Pad Change - Home